N. Engl. J. Med. 382, 692–694 (2020).
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
Neumann-Podczaska, A. et al. COVID 19 – clinical picture in the elderly population: a qualitative systematic review. Aging Dis. 11, 988–1008 (2020).
Sohrabi, C. et al. World Health Organization declares Global Emergency: a review of the 2019 novel coronavirus (COVID-19). Int. J. Surg. 76, 71–76 (2020).
Barzilai, N. et al. Geroscience in the age of COVID-19. Aging Dis. 11, 725–729 (2020).
N. Engl. J. Med. 383, 2451–2460 (2020).
JAMA 324, 1565–1567 (2020).
Leng, Z. et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 11, 216–228 (2020).
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271.e8–280.e8 (2020).
Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631–637 (2004).
JAMA 324, 782–793 (2020).
Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China JAMA Intern. Med. 180, 934–943 (2020).
Demoule, A. et al. High-flow nasal cannula in critically iii patients with severe COVID-19. Am. J. Respir. Crit. Care Med. 202, 1039–1042 (2020).
Lanzoni, G. et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl. Med. 10, 660–673 (2021).
N. Engl. J. Med. 382, 1268–1269 (2020).
Li, H. et al. Updated approaches against SARS-CoV-2. Antimicrob. Agents Chemother. 64, e00483–20 (2020).
Aging Dis. 12, 155–191 (2021).
Liang, B. et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine 99, e21429 (2020).
Iglesias, M. et al. Mesenchymal stem cells for the compassionate treatment of severe acute respiratory distress syndrome due to COVID 19. Aging Dis. 12, 360–370 (2021).
Metcalfe, S. M. Mesenchymal stem cells and management of COVID-19 pneumonia. Med. Drug Discov. 5, 100019 (2020).
Shetty, A. K. Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia. Aging Dis. 11, 462–464 (2020).
Guo, Z. et al. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia. Crit. Care 14, 420 (2020).
Front. Cell. Dev. Biol. 8, 627414 (2021).
Shi, L. et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct. Target. Ther. 6, 58 (2021).
Prockop, D. J. The exciting prospects of new therapies with mesenchymal stromal cells. Cytotherapy 19, 1–8 (2017).
Connick, P. et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 11, 150–156 (2012).
Wilson, J. G. et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir. Med. 3, 24–32 (2015).
Fisher, S. A. et al. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Cochrane Database Syst. Rev. 1, CD009768 (2019).
Metabolism 90, 1–15 (2019).
Biomed. Pharmacother. 91, 693–706 (2017).
Cell Transpl. 29, 963689720940719 (2020).
Park, Y. J. et al. Fighting the war against COVID-19 via cell-based regenerative medicine: lessons learned from 1918 Spanish flu and other previous pandemics. Stem Cell Rev. Rep. 17, 9–32 (2021).
Lee, R. H. et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5, 54–63 (2009).
Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine https://doi.org/10.1016/j.eclinm.2021.101019 (2021).
Ann. Intern Med. 172, ITC33–ITC48 (2020).
Mayo Clin. Proc. Innov. Qual. Outcomes 4, 764–766 (2020).
Pharmacol. Ther. 24, 107716 (2020).